GLP-1 Medications for Type 1 Diabetes: Off-Label Use and Evidence

The Growing Interest in GLP-1s for Type 1 Diabetes

While semaglutide and tirzepatide are primarily prescribed for Type 2 diabetes and obesity, researchers and clinicians are increasingly exploring their potential benefits for people living with Type 1 diabetes (T1D).

The rationale is compelling: many T1D patients, particularly those with insulin resistance or overweight/obesity, face similar metabolic challenges as T2D patients. GLP-1 medications address several of these challenges through mechanisms independent of pancreatic beta-cell function.

Current Research Evidence

How GLP-1s Work in Type 1 Diabetes

Unlike in Type 2 diabetes, GLP-1 medications do not stimulate insulin secretion in T1D patients (since beta cells are non-functional). Instead, their benefits come from:

Safety Considerations for T1D Patients

Expanded Safety Data and Clinical Evidence

The safety evidence for GLP-1 use in Type 1 diabetes is growing but remains less extensive than the data available for Type 2 diabetes. Most of the evidence comes from the ADJUNCT trials with liraglutide, smaller prospective studies with semaglutide, case series, and retrospective analyses rather than large randomized controlled trials specifically designed for the T1D population. Understanding the limitations and strengths of this evidence base is essential for patients and providers making informed decisions about off-label use.

The ADJUNCT ONE and ADJUNCT TWO trials provided the most rigorous data on GLP-1 use in T1D. These double-blind, placebo-controlled trials enrolled over 1,400 T1D patients and evaluated liraglutide as an adjunct to insulin therapy. The trials demonstrated modest weight loss and reduced total daily insulin doses, but they also revealed an increased incidence of hypoglycemia and a small but concerning signal for diabetic ketoacidosis events. Importantly, the DKA events occurred primarily in patients who reduced their basal insulin doses too aggressively, highlighting the critical importance of conservative insulin adjustment protocols when adding GLP-1 therapy.

More recent real-world data with semaglutide in T1D patients has been generally encouraging. Published case series from endocrinology clinics have reported average weight losses of 8 to 12% of body weight with concurrent reductions in total daily insulin of 15 to 25%. Glycemic control as measured by time-in-range on continuous glucose monitors improved in most patients, with reduced glucose variability being a particularly notable finding. However, these case series involve selected patients who were closely monitored by experienced endocrinologists, and results may not generalize to less supervised settings.

The gastroparesis question deserves special attention in T1D populations. Diabetic gastroparesis, which involves delayed stomach emptying due to autonomic neuropathy, affects a meaningful percentage of long-standing T1D patients. Since GLP-1 medications further slow gastric emptying, there is legitimate concern about worsening gastroparesis symptoms in patients who already have impaired gastric motility. Current expert consensus is that GLP-1 medications should generally be avoided in patients with established gastroparesis, and patients with autonomic neuropathy symptoms should undergo gastric emptying studies before starting GLP-1 therapy.

Insulin Adjustment Protocols When Adding GLP-1 Therapy

Safe integration of GLP-1 medications into a Type 1 diabetes insulin regimen requires careful, systematic insulin adjustments guided by frequent glucose monitoring. The primary risks of improper insulin management during GLP-1 initiation are hypoglycemia from excessive insulin relative to the now-reduced appetite and carbohydrate intake, and euglycemic DKA from overly aggressive basal insulin reduction. A structured approach to insulin adjustment reduces both risks while allowing patients to benefit from GLP-1 therapy.

Bolus insulin adjustments should typically begin before basal insulin changes. Because GLP-1 medications slow gastric emptying and reduce food intake, postprandial glucose patterns change first. Most endocrinologists recommend reducing bolus insulin doses by 10 to 20% when starting a GLP-1 medication, with further adjustments based on pre-meal and two-hour postprandial glucose readings. Patients using insulin pumps may need to adjust their insulin-to-carbohydrate ratios and consider extending bolus delivery timing to account for the slower carbohydrate absorption caused by delayed gastric emptying.

Basal insulin adjustments require more caution and should proceed gradually. The fundamental principle is that basal insulin should never be eliminated in a Type 1 diabetes patient, regardless of how effectively the GLP-1 medication reduces appetite or glucose levels. Some patients experience reduced basal insulin requirements as weight loss improves insulin sensitivity, but the reduction should be guided by fasting glucose patterns and overnight CGM data rather than by a predetermined percentage. Reducing basal insulin by more than 10 to 15% at a time without clear glucose data supporting the change increases the risk of DKA, even if blood glucose numbers appear normal.

Patients using automated insulin delivery systems, sometimes called hybrid closed-loop pumps, face unique considerations when adding GLP-1 therapy. These systems adjust basal insulin automatically based on CGM readings, which means the pump may reduce insulin delivery in response to the lower glucose values that GLP-1 therapy produces. While this automated adjustment is generally safer than manual changes, it can still mask the need for other parameter adjustments such as total daily dose settings, carbohydrate ratios, and correction factors. Regular review of pump data with the endocrinology team is essential during the first several months of combined GLP-1 and pump therapy.

Monitoring Requirements and Who Qualifies

The monitoring intensity required for safe GLP-1 use in T1D is substantially higher than what is needed for T2D patients. This increased monitoring burden reflects the greater risk profile associated with off-label use and the complex interplay between GLP-1 effects and insulin-dependent glucose management. Patients who are not able or willing to commit to the required monitoring schedule should not start GLP-1 therapy, as inadequate monitoring significantly increases the risk of adverse events.

Continuous glucose monitoring is considered essential rather than optional for T1D patients using GLP-1 medications. CGM data provides the real-time visibility needed to detect hypoglycemia trends, assess the impact of delayed gastric emptying on postprandial glucose patterns, and identify overnight glucose changes that may indicate a need for basal insulin adjustment. Patients should review their CGM data at least daily during the first month of GLP-1 therapy and share reports with their endocrinologist at least every two weeks during the initial titration period.

Blood or urine ketone monitoring adds an important safety layer. Because T1D patients are at risk for DKA even with normal glucose levels, especially during periods of reduced food intake or illness, ketone monitoring provides an early warning of insulin deficiency that glucose monitoring alone may miss. Patients should check ketones whenever they experience persistent nausea or vomiting that limits food intake, when glucose levels are unexpectedly elevated without a clear dietary explanation, during illness, and any time they feel unwell in a way that cannot be explained by the usual GLP-1 side effects.

Not every T1D patient is a suitable candidate for GLP-1 therapy. The patients most likely to benefit and least likely to experience serious complications are those with overweight or obesity defined by a BMI of 25 or above, evidence of insulin resistance such as high total daily insulin requirements relative to body weight, stable glycemic control with an A1c below 9%, no history of recurrent DKA, no documented gastroparesis, a reliable ability to monitor glucose and ketones as directed, and access to an endocrinologist experienced with both T1D management and GLP-1 pharmacology. Patients with brittle diabetes, frequent severe hypoglycemia, or unstable glycemic control should generally not add GLP-1 therapy until their baseline management is optimized.

Practical Guidance for T1D Patients

Frequently Asked Questions